| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Viatris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.55 |
| 52 Week High | US$12.60 |
| 52 Week Low | US$8.28 |
| Beta | 0.93 |
| 11 Month Change | 1.88% |
| 3 Month Change | 10.22% |
| 1 Year Change | 15.76% |
| 33 Year Change | -10.93% |
| 5 Year Change | n/a |
| Change since IPO | -31.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -3.0% | -1.9% |
| 1Y | 15.8% | -13.2% | 12.3% |
Return vs Industry: VIA exceeded the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: VIA exceeded the German Market which returned 12.3% over the past year.
Price Volatility
| VIA volatility | |
|---|---|
| VIA Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VIA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: VIA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1961 | 33,000 | Scott Smith | www.viatris.com |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Viatris Inc. Fundamentals Summary
| VIA fundamental statistics | |
|---|---|
| Market cap | €12.60b |
| Earnings (TTM) | -€589.03m |
| Revenue (TTM) | €13.88b |
0.9x
P/S Ratio-21.4x
P/E RatioIs VIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIA income statement (TTM) | |
|---|---|
| Revenue | US$15.24b |
| Cost of Revenue | US$8.79b |
| Gross Profit | US$6.45b |
| Other Expenses | US$7.10b |
| Earnings | -US$646.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 42.32% |
| Net Profit Margin | -4.24% |
| Debt/Equity Ratio | 87.6% |
How did VIA perform over the long term?
See historical performance and comparison